Replies to post #126709 on Biotech Values

[mcbio]

It entered phase 1 over three years ago. If that tells us anything.

It's a fair point and one that came up during Q&A of the CC. The new CEO seems to be committed to more rapidly developing the drug. We should have some preliminary idea of what they have, if anything, after the Phase 1 is complete. PGNX hasn't given a firm timetable I don't believe of when they expect the Phase 1 to be complete though they did guide for another interim update in the next few weeks.

[jq1234]

It entered phase 1 over three years ago. If that tells us anything.

Have you followed other ADC phase I dose escalation trials before? They do take much longer to find maximum tolerated dose. ADC in a sense is combo drug trial, it needs to start at relatively low dose, escalating dose very slowly. Roche/IMGN's T-DM took a long time even though part of the drug trastuzumab was an approved drug for the same validated target. Even SGEN's SGN30 for liquid tumor took a long time in phase I.

Antibody drugs in general take much longer to develope than small molecule drugs, but the success rates are much higher as well. Thus, time taken to develope doesn't tell you about the chance to succeed.

[poorgradstudent]

It entered phase 1 over three years ago. If that tells us anything.

<<I think the PSMA ADC is interesting and I don't think of that as middling.<<

I guess we've all forgotten about Millennium's MLN2704, the PSMA-targeting ADC (from IMGN) which was in the clinic a decade ago and never got anywhere.